Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Sclerosing Cholangitis (VISTAS)
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 7, 2021
A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 30, 2021
A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-adherent HIV-Infected Individuals (The LATITUDE Study)
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 10, 2021
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2021
Transoral Incisionless Fundoplication (TIF) Registry
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 17, 2021
Accelerated TMS for Depression and OCD
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 31, 2021
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects with Type 2 Diabetes on Insulin Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 2, 2021
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 5, 2021
A Randomized Phase 3 Trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 26, 2021
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination with Ruxolitinib in Participants with Anemia Due to Myeloproliferative Disorders
Study Status:
Open to Enrollment
Primary Investigator:
Date: November 24, 2021